

Figure S1: Intensive care unit (ICU) map. Floorplan of the ICU where this study was conducted. Blue numbers refer to bed units and red numbers to rooms.











A**B****C****D****E****F****G****H****I**


Figure S2: Distribution of MICs for 9 antimicrobial agents against of 518 *A. baumanii*. A) imipenem; B) meropenem; C) sulbactam; D) polymyxin; E) tigecycline; F) amikacin; G) cefoperazone/sulbactam (1:1); H) cefoperazone/sulbactam (2:1); I) ciprofloxacin.

Notes: 1) As there is no tigecycline breakpoint for *Acinetobacter*, MICs were interpreted following the FDA guidelines for Enterobacterales (with MICs ≤ 2 mg/L denoting susceptibility and ≥ 8 mg/L denoting resistance). 2) As there is no breakpoint for cefoperazone/sulbactam, results were interpreted according to the CLSI 2021 ampicillin/sulbactam guidelines.

A. Patient isolates



B. Environmental isolates






Figure S4: Acquisition of Tn2006 by pDETAB10. Scaled schematic diagrams of the R3-T1 plasmids pDETAB10 and pDETAB10::Tn2006. The plasmid backbone is shown as a black line, the insertion sequence ISAb1 as navy boxes, and the Tn2006 passenger segment as a light blue line. Open reading frames are shown as labelled arrows. The locations of target site duplications and pdif sites are indicated as shown in the key to the left of the figure.